Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study
The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SC...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-07, Vol.17 (7), p.e0271907 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | e0271907 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Wakasaki, Takahiro Manako, Tomomi Yasumatsu, Ryuji Hara, Hirotaka Toh, Satoshi Masuda, Muneyuki Yamauchi, Moriyasu Kuratomi, Yuichiro Nishimura, Emi Takeuchi, Toranoshin Matsuo, Mioko Jiromaru, Rina Hashimoto, Kazuki Komune, Noritaka Nakagawa, Takashi |
| description | The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration.
We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45).
The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B.
Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended. |
| doi_str_mv | 10.1371/journal.pone.0271907 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2695866151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A711807614</galeid><doaj_id>oai_doaj_org_article_6b838054b0db431388ae8c3d7133aafb</doaj_id><sourcerecordid>A711807614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-bdc722dff4b04e3f430f15c4dfd17df6501fad7e85ef3a419d78a6e85c4d76ff3</originalsourceid><addsrcrecordid>eNqNk11rFDEUhgdRbK3-A9GAIHixazKZTy-EUqoWCoJft-FMcrKbNpNsk0zb_a_-GNPttnRBQQZmkpznfXNyJqcoXjI6Z7xl78_8FBzY-co7nNOyZT1tHxX7rOflrCkpf_xgvFc8i_GM0pp3TfO02ON1Txntu_3i97HWKJO5RIcxEnCKRNCY1sRrcoV4btdkBdKaBNdoN3GJabo2IwwEsiDj9hIWSOQSR5-WGGC1Jtpb66-MWxAzjpPbROX5yhuXiHFLM5jkQ8xYIAHlFALmQJ6MmCAmSEaSJYLa7OeyksSLCUY_xby7tURCkMb5ET6QQzJONvPZAAPJiTojwZKYJrV-XjzRYCO-2H4Pip-fjn8cfZmdfv18cnR4OpNt3aXZoGRblkrraqAVcl1xqlktK6UVa5Vuaso0qBa7GjWHivWq7aDJ04y0jdb8oHh967uyPortj4mibPo615vVLBMnt4TycCZWIZcvrIUHIzYLPiwEhHwKi6IZOt7ROueihooz3nWAneSqZZwD6CF7fdzuNg0jqpuTB7A7prsRZ5Zi4S9Fzzkv8-ugeLM1CP5iwpj-kfKWWkDOyjjts5kcTZTisGWso23DqkzN_0LlR-FoZL6a2uT1HcG7HUFmEl6nBUwxipPv3_6f_fprl337gM2Xx6Zl9HZKxru4C1a3oAw-xoD6vnKMipvOuquGuOksse2sLHv1sOr3ortW4n8A6NsmAQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2695866151</pqid></control><display><type>article</type><title>Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wakasaki, Takahiro ; Manako, Tomomi ; Yasumatsu, Ryuji ; Hara, Hirotaka ; Toh, Satoshi ; Masuda, Muneyuki ; Yamauchi, Moriyasu ; Kuratomi, Yuichiro ; Nishimura, Emi ; Takeuchi, Toranoshin ; Matsuo, Mioko ; Jiromaru, Rina ; Hashimoto, Kazuki ; Komune, Noritaka ; Nakagawa, Takashi</creator><creatorcontrib>Wakasaki, Takahiro ; Manako, Tomomi ; Yasumatsu, Ryuji ; Hara, Hirotaka ; Toh, Satoshi ; Masuda, Muneyuki ; Yamauchi, Moriyasu ; Kuratomi, Yuichiro ; Nishimura, Emi ; Takeuchi, Toranoshin ; Matsuo, Mioko ; Jiromaru, Rina ; Hashimoto, Kazuki ; Komune, Noritaka ; Nakagawa, Takashi</creatorcontrib><description>The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration.
We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45).
The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B.
Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0271907</identifier><identifier>PMID: 35901098</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biology and Life Sciences ; Cancer ; Care and treatment ; Cetuximab - adverse effects ; Chemotherapy ; Diagnosis ; Disease control ; Dosage and administration ; Head & neck cancer ; Head and neck cancer ; Head and neck carcinoma ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - etiology ; Humans ; Immune Checkpoint Inhibitors ; Medical imaging ; Medical records ; Medicine and Health Sciences ; Metastases ; Metastasis ; Monoclonal antibodies ; Neoplasm Recurrence, Local - pathology ; Paclitaxel ; Paclitaxel - adverse effects ; Patient outcomes ; Patients ; Performance evaluation ; Pneumonia ; Prevention ; Research and Analysis Methods ; Retrospective Studies ; Risk factors ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Squamous Cell Carcinoma of Head and Neck - etiology ; Survival ; Targeted cancer therapy ; Tumors</subject><ispartof>PloS one, 2022-07, Vol.17 (7), p.e0271907</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Wakasaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Wakasaki et al 2022 Wakasaki et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-bdc722dff4b04e3f430f15c4dfd17df6501fad7e85ef3a419d78a6e85c4d76ff3</citedby><cites>FETCH-LOGICAL-c758t-bdc722dff4b04e3f430f15c4dfd17df6501fad7e85ef3a419d78a6e85c4d76ff3</cites><orcidid>0000-0002-5765-9418 ; 0000-0001-7736-9162 ; 0000-0002-7719-4187</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333293/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333293/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35901098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wakasaki, Takahiro</creatorcontrib><creatorcontrib>Manako, Tomomi</creatorcontrib><creatorcontrib>Yasumatsu, Ryuji</creatorcontrib><creatorcontrib>Hara, Hirotaka</creatorcontrib><creatorcontrib>Toh, Satoshi</creatorcontrib><creatorcontrib>Masuda, Muneyuki</creatorcontrib><creatorcontrib>Yamauchi, Moriyasu</creatorcontrib><creatorcontrib>Kuratomi, Yuichiro</creatorcontrib><creatorcontrib>Nishimura, Emi</creatorcontrib><creatorcontrib>Takeuchi, Toranoshin</creatorcontrib><creatorcontrib>Matsuo, Mioko</creatorcontrib><creatorcontrib>Jiromaru, Rina</creatorcontrib><creatorcontrib>Hashimoto, Kazuki</creatorcontrib><creatorcontrib>Komune, Noritaka</creatorcontrib><creatorcontrib>Nakagawa, Takashi</creatorcontrib><title>Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration.
We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45).
The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B.
Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biology and Life Sciences</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cetuximab - adverse effects</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease control</subject><subject>Dosage and administration</subject><subject>Head & neck cancer</subject><subject>Head and neck cancer</subject><subject>Head and neck carcinoma</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - etiology</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors</subject><subject>Medical imaging</subject><subject>Medical records</subject><subject>Medicine and Health Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Paclitaxel</subject><subject>Paclitaxel - adverse effects</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Performance evaluation</subject><subject>Pneumonia</subject><subject>Prevention</subject><subject>Research and Analysis Methods</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - etiology</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11rFDEUhgdRbK3-A9GAIHixazKZTy-EUqoWCoJft-FMcrKbNpNsk0zb_a_-GNPttnRBQQZmkpznfXNyJqcoXjI6Z7xl78_8FBzY-co7nNOyZT1tHxX7rOflrCkpf_xgvFc8i_GM0pp3TfO02ON1Txntu_3i97HWKJO5RIcxEnCKRNCY1sRrcoV4btdkBdKaBNdoN3GJabo2IwwEsiDj9hIWSOQSR5-WGGC1Jtpb66-MWxAzjpPbROX5yhuXiHFLM5jkQ8xYIAHlFALmQJ6MmCAmSEaSJYLa7OeyksSLCUY_xby7tURCkMb5ET6QQzJONvPZAAPJiTojwZKYJrV-XjzRYCO-2H4Pip-fjn8cfZmdfv18cnR4OpNt3aXZoGRblkrraqAVcl1xqlktK6UVa5Vuaso0qBa7GjWHivWq7aDJ04y0jdb8oHh967uyPortj4mibPo615vVLBMnt4TycCZWIZcvrIUHIzYLPiwEhHwKi6IZOt7ROueihooz3nWAneSqZZwD6CF7fdzuNg0jqpuTB7A7prsRZ5Zi4S9Fzzkv8-ugeLM1CP5iwpj-kfKWWkDOyjjts5kcTZTisGWso23DqkzN_0LlR-FoZL6a2uT1HcG7HUFmEl6nBUwxipPv3_6f_fprl337gM2Xx6Zl9HZKxru4C1a3oAw-xoD6vnKMipvOuquGuOksse2sLHv1sOr3ortW4n8A6NsmAQ</recordid><startdate>20220728</startdate><enddate>20220728</enddate><creator>Wakasaki, Takahiro</creator><creator>Manako, Tomomi</creator><creator>Yasumatsu, Ryuji</creator><creator>Hara, Hirotaka</creator><creator>Toh, Satoshi</creator><creator>Masuda, Muneyuki</creator><creator>Yamauchi, Moriyasu</creator><creator>Kuratomi, Yuichiro</creator><creator>Nishimura, Emi</creator><creator>Takeuchi, Toranoshin</creator><creator>Matsuo, Mioko</creator><creator>Jiromaru, Rina</creator><creator>Hashimoto, Kazuki</creator><creator>Komune, Noritaka</creator><creator>Nakagawa, Takashi</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5765-9418</orcidid><orcidid>https://orcid.org/0000-0001-7736-9162</orcidid><orcidid>https://orcid.org/0000-0002-7719-4187</orcidid></search><sort><creationdate>20220728</creationdate><title>Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study</title><author>Wakasaki, Takahiro ; Manako, Tomomi ; Yasumatsu, Ryuji ; Hara, Hirotaka ; Toh, Satoshi ; Masuda, Muneyuki ; Yamauchi, Moriyasu ; Kuratomi, Yuichiro ; Nishimura, Emi ; Takeuchi, Toranoshin ; Matsuo, Mioko ; Jiromaru, Rina ; Hashimoto, Kazuki ; Komune, Noritaka ; Nakagawa, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-bdc722dff4b04e3f430f15c4dfd17df6501fad7e85ef3a419d78a6e85c4d76ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biology and Life Sciences</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cetuximab - adverse effects</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease control</topic><topic>Dosage and administration</topic><topic>Head & neck cancer</topic><topic>Head and neck cancer</topic><topic>Head and neck carcinoma</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - etiology</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors</topic><topic>Medical imaging</topic><topic>Medical records</topic><topic>Medicine and Health Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Paclitaxel</topic><topic>Paclitaxel - adverse effects</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Performance evaluation</topic><topic>Pneumonia</topic><topic>Prevention</topic><topic>Research and Analysis Methods</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - etiology</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wakasaki, Takahiro</creatorcontrib><creatorcontrib>Manako, Tomomi</creatorcontrib><creatorcontrib>Yasumatsu, Ryuji</creatorcontrib><creatorcontrib>Hara, Hirotaka</creatorcontrib><creatorcontrib>Toh, Satoshi</creatorcontrib><creatorcontrib>Masuda, Muneyuki</creatorcontrib><creatorcontrib>Yamauchi, Moriyasu</creatorcontrib><creatorcontrib>Kuratomi, Yuichiro</creatorcontrib><creatorcontrib>Nishimura, Emi</creatorcontrib><creatorcontrib>Takeuchi, Toranoshin</creatorcontrib><creatorcontrib>Matsuo, Mioko</creatorcontrib><creatorcontrib>Jiromaru, Rina</creatorcontrib><creatorcontrib>Hashimoto, Kazuki</creatorcontrib><creatorcontrib>Komune, Noritaka</creatorcontrib><creatorcontrib>Nakagawa, Takashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wakasaki, Takahiro</au><au>Manako, Tomomi</au><au>Yasumatsu, Ryuji</au><au>Hara, Hirotaka</au><au>Toh, Satoshi</au><au>Masuda, Muneyuki</au><au>Yamauchi, Moriyasu</au><au>Kuratomi, Yuichiro</au><au>Nishimura, Emi</au><au>Takeuchi, Toranoshin</au><au>Matsuo, Mioko</au><au>Jiromaru, Rina</au><au>Hashimoto, Kazuki</au><au>Komune, Noritaka</au><au>Nakagawa, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-07-28</date><risdate>2022</risdate><volume>17</volume><issue>7</issue><spage>e0271907</spage><pages>e0271907-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration.
We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45).
The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B.
Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35901098</pmid><doi>10.1371/journal.pone.0271907</doi><tpages>e0271907</tpages><orcidid>https://orcid.org/0000-0002-5765-9418</orcidid><orcidid>https://orcid.org/0000-0001-7736-9162</orcidid><orcidid>https://orcid.org/0000-0002-7719-4187</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-07, Vol.17 (7), p.e0271907 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2695866151 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Antineoplastic Combined Chemotherapy Protocols - adverse effects Biology and Life Sciences Cancer Care and treatment Cetuximab - adverse effects Chemotherapy Diagnosis Disease control Dosage and administration Head & neck cancer Head and neck cancer Head and neck carcinoma Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - etiology Humans Immune Checkpoint Inhibitors Medical imaging Medical records Medicine and Health Sciences Metastases Metastasis Monoclonal antibodies Neoplasm Recurrence, Local - pathology Paclitaxel Paclitaxel - adverse effects Patient outcomes Patients Performance evaluation Pneumonia Prevention Research and Analysis Methods Retrospective Studies Risk factors Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - etiology Survival Targeted cancer therapy Tumors |
| title | Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A04%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20weekly%20paclitaxel%20and%20cetuximab%20as%20a%20salvage%20chemotherapy%20following%20immune%20checkpoint%20inhibitors%20for%20recurrent%20or%20metastatic%20head%20and%20neck%20squamous%20cell%20carcinoma:%20A%20multicenter%20clinical%20study&rft.jtitle=PloS%20one&rft.au=Wakasaki,%20Takahiro&rft.date=2022-07-28&rft.volume=17&rft.issue=7&rft.spage=e0271907&rft.pages=e0271907-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0271907&rft_dat=%3Cgale_plos_%3EA711807614%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2695866151&rft_id=info:pmid/35901098&rft_galeid=A711807614&rft_doaj_id=oai_doaj_org_article_6b838054b0db431388ae8c3d7133aafb&rfr_iscdi=true |